The CHF application of TCL Analyzer™ measures values that are correlated to known prognostic markers for deterioration of CHF.

 

TCL Analyzer™ uses oxidative stress status and oxidizability as biomarkers for assessing CHF severity and expected deterioration. It is not limited to any particular symptom of CHF or any particular cause of it. As such, TCL Analyzer™ is an important risk stratification tool, alerting caregivers to a potential need for hospitalization within a 1 to 4 month period.

 

Studies of TCL analysis in heart failure patients found that TCL Analyzer™ values highly correlate with currently used (but highly costly) diagnostic markers.

The ability to predict if a patient's heart failure situation may soon decline provides caregivers with a highly valuable decision-supporting tool. A false positive decision translates into unnecessary hospitalization costs, inconvenience, and loss of patient's time, whereas a false negative decision means health risk to the patient with all its implications.

TCL Analyzer™ is suited for point-of-care units of CHF patients as an early alert on deterioration of CHF, and as a monitor for treatment efficacy.

TCL Analyzer™ meets needs for a diagnostic tool for clinical prediction of CHF and CHF deterioration. It is a low-cost device that is rapid, simple-to-use, and can be used by healthcare professionals without special training in any point of care.

In the world's aging population, there are millions of severe heart failure sufferers and the number is steadily growing. Patients require 3-4 TCL tests each year as part of their monitoring and treatment regime.